Cargando…

Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy

Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage breast cancer (ESBC) with an intermediate risk (10–20%) of febrile neutropenia (FN). Secondary prophylaxis of granulocyte colony-stimulating factor (G-CSF) is considered in patients receiving AC-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jae Hee, Geum, Min Jung, Kang, Ji Eun, Park, Nam Gi, Oh, Yun Kyoung, Rhie, Sandy Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620630/
https://www.ncbi.nlm.nih.gov/pubmed/34832982
http://dx.doi.org/10.3390/ph14111200
_version_ 1784605266608652288
author Choi, Jae Hee
Geum, Min Jung
Kang, Ji Eun
Park, Nam Gi
Oh, Yun Kyoung
Rhie, Sandy Jeong
author_facet Choi, Jae Hee
Geum, Min Jung
Kang, Ji Eun
Park, Nam Gi
Oh, Yun Kyoung
Rhie, Sandy Jeong
author_sort Choi, Jae Hee
collection PubMed
description Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage breast cancer (ESBC) with an intermediate risk (10–20%) of febrile neutropenia (FN). Secondary prophylaxis of granulocyte colony-stimulating factor (G-CSF) is considered in patients receiving AC-based chemotherapy; however, relevant studies are limited. Here, we retrospectively reviewed the electronic medical records of 320 patients who completed adjuvant AC-based chemotherapy from September 2016 to September 2020. Approximately 46.6% of the patients developed severe neutropenic events (SNE) during AC-based chemotherapy. Secondary prophylaxis of G-CSF reduced the risk of recurrent SNE (p < 0.01) and the relative dose intensity (RDI) < 85% (p = 0.03) in patients who had experienced SNE during AC-based chemotherapy. Age ≥ 65 years (p = 0.02) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 60 IU/L (p = 0.04) were significant risk factors for RDI < 85%. The incidences of FN, grade 4 neutropenia, unscheduled hospitalization, and interruption to the dosing regimen were reduced in patients administered secondary prophylaxis with G-CSF (before vs. after administration: FN, 19.4% vs. 4.6%; grade 4 neutropenia, 86.1% vs. 14.8%; unscheduled hospitalization, 75.9% vs. 11.1%; interruption to the dosing regimen, 18.5% vs. 8.3%). This study indicated the importance of active intervention of G-CSF use to prevent recurrent SNE and improve clinical outcomes in patients with breast cancer who receive AC-based chemotherapy.
format Online
Article
Text
id pubmed-8620630
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86206302021-11-27 Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy Choi, Jae Hee Geum, Min Jung Kang, Ji Eun Park, Nam Gi Oh, Yun Kyoung Rhie, Sandy Jeong Pharmaceuticals (Basel) Article Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage breast cancer (ESBC) with an intermediate risk (10–20%) of febrile neutropenia (FN). Secondary prophylaxis of granulocyte colony-stimulating factor (G-CSF) is considered in patients receiving AC-based chemotherapy; however, relevant studies are limited. Here, we retrospectively reviewed the electronic medical records of 320 patients who completed adjuvant AC-based chemotherapy from September 2016 to September 2020. Approximately 46.6% of the patients developed severe neutropenic events (SNE) during AC-based chemotherapy. Secondary prophylaxis of G-CSF reduced the risk of recurrent SNE (p < 0.01) and the relative dose intensity (RDI) < 85% (p = 0.03) in patients who had experienced SNE during AC-based chemotherapy. Age ≥ 65 years (p = 0.02) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 60 IU/L (p = 0.04) were significant risk factors for RDI < 85%. The incidences of FN, grade 4 neutropenia, unscheduled hospitalization, and interruption to the dosing regimen were reduced in patients administered secondary prophylaxis with G-CSF (before vs. after administration: FN, 19.4% vs. 4.6%; grade 4 neutropenia, 86.1% vs. 14.8%; unscheduled hospitalization, 75.9% vs. 11.1%; interruption to the dosing regimen, 18.5% vs. 8.3%). This study indicated the importance of active intervention of G-CSF use to prevent recurrent SNE and improve clinical outcomes in patients with breast cancer who receive AC-based chemotherapy. MDPI 2021-11-22 /pmc/articles/PMC8620630/ /pubmed/34832982 http://dx.doi.org/10.3390/ph14111200 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Choi, Jae Hee
Geum, Min Jung
Kang, Ji Eun
Park, Nam Gi
Oh, Yun Kyoung
Rhie, Sandy Jeong
Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
title Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
title_full Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
title_fullStr Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
title_full_unstemmed Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
title_short Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
title_sort clinical outcomes of secondary prophylactic granulocyte colony-stimulating factors in breast cancer patients at a risk of neutropenia with doxorubicin and cyclophosphamide-based chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620630/
https://www.ncbi.nlm.nih.gov/pubmed/34832982
http://dx.doi.org/10.3390/ph14111200
work_keys_str_mv AT choijaehee clinicaloutcomesofsecondaryprophylacticgranulocytecolonystimulatingfactorsinbreastcancerpatientsatariskofneutropeniawithdoxorubicinandcyclophosphamidebasedchemotherapy
AT geumminjung clinicaloutcomesofsecondaryprophylacticgranulocytecolonystimulatingfactorsinbreastcancerpatientsatariskofneutropeniawithdoxorubicinandcyclophosphamidebasedchemotherapy
AT kangjieun clinicaloutcomesofsecondaryprophylacticgranulocytecolonystimulatingfactorsinbreastcancerpatientsatariskofneutropeniawithdoxorubicinandcyclophosphamidebasedchemotherapy
AT parknamgi clinicaloutcomesofsecondaryprophylacticgranulocytecolonystimulatingfactorsinbreastcancerpatientsatariskofneutropeniawithdoxorubicinandcyclophosphamidebasedchemotherapy
AT ohyunkyoung clinicaloutcomesofsecondaryprophylacticgranulocytecolonystimulatingfactorsinbreastcancerpatientsatariskofneutropeniawithdoxorubicinandcyclophosphamidebasedchemotherapy
AT rhiesandyjeong clinicaloutcomesofsecondaryprophylacticgranulocytecolonystimulatingfactorsinbreastcancerpatientsatariskofneutropeniawithdoxorubicinandcyclophosphamidebasedchemotherapy